Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S2–S10 | Cite as

In vitro activity and mode of action of fluoroquinolones

  • L. Verbist


The in vitro activity of nine fluoroquinolones has been determined by agar dilution method against 1100 clinical isolates of different microorganisms: 412Enterobacteriaceae, 93 non-fermenters, 398 enteropathogens, 140 Grampositive cocci, 31Haemophilus and 26 gonococci. The bactericidal activity tested in broth against different representative isolates was generally similar to the inhibitory concentration. Killing kinetics studied in different isolates ofEnterobacteriaceae, inPseudomonas aeruginosa, Vibrio cholerae, Staphylococcus aureus andStreptococcus faecalis showed a very rapid bactericidal effect, after 2 to 8 h of contact, in all species except inStreptococcus faecalis.

Key words

In vitro activity Killing kinetics Quinolones 


  1. 1.
    Crumplin GC, Smith JT. Nalidixic acid and bacterial chromosone replication. Nature 1976;260:643–5.PubMedGoogle Scholar
  2. 2.
    Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Nat Acad Sci USA 1976;73:3872–6.PubMedGoogle Scholar
  3. 3.
    Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa JL. Nalidìxic acid resistance: a second character involved in DNA gyrase activity. Proc Nat Acad Sciences Usa 1977;74:4772–6.Google Scholar
  4. 4.
    Crumplin GC, Smith JT. Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 1975;8:251–1.PubMedGoogle Scholar
  5. 5.
    Smith JT. Awakening the slumbering potential of the 4-quinolones antibacterials. Pharm J 1984;233:299–305.Google Scholar
  6. 6.
    Crumplin GC, Kenwright M, Hirst T. Investigation into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother 1984;13 (Suppl b):9–23.Google Scholar
  7. 7.
    Smith JT. The mode of action of 4-quinolones and possible mechanisms of-resistance. J Antimicrob Chemother 1986;18 (Suppl.d):21–9.PubMedGoogle Scholar
  8. 8.
    Verbist L. Quinolones: pharmacology. Pharm Weekbl [Sci] 1986;8:22–5.Google Scholar
  9. 9.
    Diridl G, Pichler H, Wolf D. Treatment of chronicSalmonella carriers with ciprofloxacin. Eur J Clin Microb 1986;5:260–261.Google Scholar
  10. 10.
    Ericsson CD, Johnson PC, Dupont HL, Bitsura JH, De la Cabada FJ. A comparison of ciprofloxacin and trimethoprim/ sulfamethoxazole in the treatment of acute diarrhea among U.S. adults in Mexico. Clin Res 1985;33:563a.Google Scholar
  11. 11.
    Pichler H, Diridl G, Wolf D. Ciprofloxacin in the treatment of acute bacterial diarrhoea: a double blind study. Eur J Clin Microbiol 1986;5:241–3.PubMedGoogle Scholar
  12. 12.
    Rogerie F, Ott D, Vandepitte J, Verbist L, Lemmens P, Habiyaremye I. Comparison of norfloxacin and nalidixic acid for the treatment of dysentery caused by shigella dysenteriae type 1 in adults. Antimicrob Agents Chemother 1986;29:883–6.PubMedGoogle Scholar
  13. 13.
    Fallon RJ, Brown WM.In vitro sensitivity ofLegionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin. J Antimicrob Chemother 1985;15:6.Google Scholar
  14. 14.
    Pohlod DJ, Saravolatz LD. Activity of quinolones against legionellaceae. J Antimicrob Chemother 1986;17:540–1.PubMedGoogle Scholar
  15. 15.
    Saito A, Hironobu K, Shigeno H, Watanabe K, Mori K, Kohno S, Shigeno Y, Suzuyama Y, Yamaguchi K, Hirota M, Hara K. The antimicrobial activity of ciprofloxacin againstLegionella species and the treatment of experimentalLegionella pneumoniae in guinea pigs. J Antimicrob Chemother 1986;18:51–60.Google Scholar
  16. 16.
    Ridgway GL, Mumtaz G, Gabriel FG, Oriel JD. The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis and mycoplasmasin vitro. Eur J Clin Microb 1984;3:344–6.Google Scholar
  17. 17.
    Crider SR, Colby SD, Miller LK, Harrison WO, Kerbs SBJ, Berg SW. Treatment of penicillin-resistantNeisseria gonorrhoeae with oral norfloxacin. N Engl J Med 1984;311:137–40.PubMedGoogle Scholar
  18. 18.
    Notswicz A, Stolz E, Van Klingeren B. A double blind study comparing two dosages of enoxacin for the treatment of uncomplicated urogenital gonorrhoea. J Antimicrob Chemother 1984;14:91–4.Google Scholar
  19. 19.
    Loo PS, Ridgway GL, Oriel JD. Single dose ciprofloxacin for treating gonococcal infections in men. Genitourinary Med 1985;61:302–5.Google Scholar
  20. 20.
    Bogaerts J, Martinez Tello W, Verbist L, Piot P, Vandepitte J. Norfloxacin versus thiamphenicol for treatment of uncomplicated fonorrhea in Rwanda. Antimicrob Agents Chemother 1987;31:434–7.PubMedGoogle Scholar
  21. 21.
    Van Roosbroeck RJ, Privinciael DR, Van Caekenberghe DL. Activity of the newer quinolones againstChlamydia trachomatis. Br J Vener Dis 1984;60:350.Google Scholar
  22. 22.
    Stolz E, Tegelberg-Stassen MJA, Van der Willigen AH, Van der Hoek JCS, Jan Joost TH, Mooi L, Wagenvoort JHT. Quinolones in the treatment of gonorrhoea andChlamydia trachomatis infections. Pharm Weekbl (Sci) 1986;8:60–2.Google Scholar
  23. 23.
    Fong IW. Treatment of chlamydial urethritis with ofloxacin or ciprofloxacin. Quinolones Bull 1986;2:10–1.Google Scholar
  24. 24.
    King A, Phillips I. The comparativein vitro activity of eight newer quinolones and naladixic acid. J Antimicrob Chemother 1986;18 (Suppl. D):1–20.Google Scholar
  25. 25.
    Reeves DS. The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibactirials. J Antimicrob Chemother 1986;18 (Suppl d):89–102.PubMedGoogle Scholar
  26. 26.
    Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukaemia during remission induction treatment: the effect on faecal flora. J Infect Dis 1985;152:104–7.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • L. Verbist
    • 1
  1. 1.Diagnostic Microbiology LaboratoryUniversity Hospital St RafaelLeuvenBelgium

Personalised recommendations